Follow
Elora Kalita
Title
Cited by
Cited by
Year
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies
M Panda, E Kalita, S Singh, K Kumar, A Rao, VK Prajapati
Life Sciences 305, 120761, 2022
322022
Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics
M Panda, E Kalita, S Singh, K Kumar, VK Prajapati
Molecular Diversity 27 (6), 2577-2603, 2023
72023
Mechanism of cell cycle regulation and cell proliferation during human viral infection
M Panda, E Kalita, A Rao, VK Prajapati
Advances in Protein Chemistry and Structural Biology 135, 497-525, 2023
22023
Application of functional proteomics in understanding RNA virus-mediated infection.
M Panda, E Kalita, S Singh, A Rao, VK Prajapati
Advances in Protein Chemistry and Structural Biology 138, 301-325, 2023
2023
The interplay between circadian clock and viral infections: A molecular perspective
E Kalita, M Panda, VK Prajapati
Advances in Protein Chemistry and Structural Biology 137, 293-330, 2023
2023
Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics
E Kalita, M Panda, A Rao, VK Prajapati
Advances in Protein Chemistry and Structural Biology 133, 231-269, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–6